Experimental Alzheimer’s Drug Could Eventually Offer a Treatment Breakthrough

An experimental drug used to treat Alzheimer’s disease removed toxic plaques in patients’ brains, according to researchers.

The trial drug, Aducanumab, was given to patients with early-stage Alzheimer’s disease once a month for a year. It cleared the brain’s toxic plaque deposits, which experts believe are the leading cause of Alzheimer’s.

As we age, most of our brains will have the plaque deposits, but in those with Alzheimer’s disease, there is much more present.

The study used PET scans to measure the success of the trial on 165 patients. Every group that received the drug had a reduction in their plaque deposits over time, and the group that got the highest dosage had the greatest reduction.

See Also

However, experts say that the study didn’t have enough patients to prove that it works. Previous treatments to slow or reverse the disease’s progression have been unsuccessful.

But, many researchers are remaining cautiously optimistic. Larger trials are being planned and will run at least until 2020.

Scroll To Top

DON'T MISS
A THING

Get RELEVANT's Top STORIES EVERY MORNING

Start your weekdays with “RELEVANT Today”—a quick look at our five most trending articles.